Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Neurology Neurosurgery & Psychiatry

• Publication date

  2008-06-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/jnnp.2008.143875PMID 18535024
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial.

  2007cited by this paper
• Aspirin plus dipyridamole was more effective than aspirin alone for preventing vascular events after minor cerebral ischaemia

  2006cited by this paper
• Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.

  2006cited by this paper
• Antiplatelet Drugs In the Secondary Prevention After Stroke: Differential Efficacy in Large Versus Small Vessel Disease? A Subgroup Analysis From ESPS-2

  2006cited by this paper
• Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.

  2006cited by this paper
• Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin.

  2006cited by this paper
• Investigating heterogeneity in an individual patient data meta‐analysis of time to event outcomes

  2005cited by this paper
• Dipyridamole for Preventing Recurrent Ischemic Stroke and Other Vascular Events: A Meta-Analysis of Individual Patient Data From Randomized Controlled Trials

  2005cited by this paper
• Modified-release dipyridamole combined with aspirin for secondary stroke prevention

  2005cited by this paper
• Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.

  2005cited by this paper
• Efficacy of aspirin plus extended-release dipyridamole in preventing recurrent stroke in high-risk populations.

  2005cited by this paper
• Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.

  2004cited by this paper
• Secondary Prevention of Stroke

  2004cited by this paper
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

  2002cited by this paper
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

  2002cited by this paper
• The way I see it: House officers need formal career development

  2002cited by this paper
• Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin.

  2001cited by this paper
• A COMPARISON OF WARFARIN AND ASPIRIN FOR THE PREVENTION OF RECURRENT ISCHEMIC STROKE

  2001cited by this paper
• A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke.

  2001cited by this paper
• Secondary prevention after cerebral ischaemia of presumed arterial origin: is aspirin still the touchstone?

  1999cited by this paper
• Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin

  1999cited by this paper
• We need stronger predictors of major vascular events in patients with a recent transient ischemic attack or nondisabling stroke. Dutch TIA Trial Study Group.

  1997cited by this paper
• Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.

  1997cited by this paper
• A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin

  1997cited by this paper
• European stroke prevention study 2: Efficacy and safety data

  1997cited by this paper
• Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia.

  1996cited by this paper
• European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.

  1996cited by this paper
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

  1996cited by this paper
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

  1996cited by this paper
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)

  1996cited by this paper
• Recurrent stroke after transient ischaemic attack or minor ischaemic stroke: does the distinction between small and large vessel disease remain true to type? Dutch TIA Trial Study Group.

  1995cited by this paper
• Meta-analysis of the literature or of individual patient data: is there a difference?

  1993cited by this paper
• Predictors of Major Vascular Events in Patients With a Transient Ischemic Attack or Nondisabling Stroke

  1993cited by this paper
• Trial of Secondary Prevention With Atenolol After Transient Ischemic Attack or Nondisabling Ischemic Stroke

  1993cited by this paper
• Secondary prevention of stroke.

  1992cited by this paper
• The European Stroke Prevention Study

  1991cited by this paper
• A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke.

  1991cited by this paper
• Persantine Aspirin Trial in cerebral ischemia. Part II: Endpoint results. The American-Canadian Co-Operative Study group.

  1985cited by this paper
• Persantine Aspirin Trial in cerebral ischemia. Part II: Endpoint results. The American-Canadian Co-Operative Study group.

  1985cited by this paper
• "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia.

  1983cited by this paper
• [Prevention of recurrences of cerebral ischemic vascular accidents by platelet antiaggregants. Results of a 3-year controlled therapeutic trial].

  1982cited by this paper

• Impact of CYP2C19 genotyping on clopidogrel therapy adjustments in patients with stroke or TIA

  2026cites this paper
• Clinical and cost-effectiveness of clopidogrel resistance genotype testing after ischaemic stroke or transient ischaemic attack: a systematic review and economic model.

  2024cites this paper
• Antiplatelet therapy in the prevention of recurrent ischemic stroke

  2024cites this paper
• Repeated ischemic stroke and its prevention

  2024cites this paper
• Novel strategies in antithrombotic therapy: targeting thrombosis while preserving hemostasis

  2023cites this paper
• Antiplatelet therapy after noncardioembolic ischemic stroke or transient ischemic attack

  2022cites this paper
• Antiplatelet treatment for acute secondary prevention of non-cardioembolic minor stroke / transient ischaemic attack: an update for the acute physician.

  2022cites this paper
• Effects of Dose Titration on Dipyridamole-Induced Headache: A Randomized, Double-Blind Clinical Trial

  2022cites this paper
• Antiplatelet Use in Ischemic Stroke

  2022cites this paper
• Oral antithrombotic therapy for the prevention of recurrent cerebrovascular events.

  2021cites this paper
• Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack

  2021cites this paper
• The methodological quality of individual participant data meta-analysis on intervention effects: systematic review

  2021cites this paper
• Antiplatelet Therapy for Transient Ischemic Attack and Minor Stroke.

  2020cites this paper
• Remote platelet function testing using P-selectin expression in patients with recent cerebral ischaemia on clopidogrel

  2020cites this paper
• Transient ischemic attacks: a single institutional experience

  2020cites this paper
• Data sharing: experience of accessing individual patient data from completed randomised controlled trials in vascular and cognitive medicine

  2020cites this paper
• Reducing the impact of stroke and improving public health

  2019cites this paper
• Primärprävention und Sekundärprävention des Hirninfarkts

  2019cites this paper
• Antiplatelet Therapy in Ischemic Stroke and Transient Ischemic Attack.

  2019cites this paper
• Dipyridamole plus Triflusal versus Triflusal Alone in Infarct Reduction after Middle Cerebral Artery Occlusion.

  2018cites this paper
• Aspirin plus dipyridamole has the highest surface under the cumulative ranking curves (SUCRA) values in terms of mortality, intracranial hemorrhage, and adverse event rate among 7 drug therapies in the treatment of cerebral infarction

  2018cites this paper
• Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases

  2018cites this paper
• Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT.

  2018cites this paper
• Reversal of Systemic Anticoagulants and Antiplatelet Therapeutics.

  2018cites this paper
• Remote Assessment of Platelet Function in Patients with Acute Stroke or Transient Ischaemic Attack

  2017cites this paper
• Baseline characteristics of the 3096 patients recruited into the ‘Triple Antiplatelets for Reducing Dependency after Ischemic Stroke’ trial

  2017cites this paper
• Effectiveness and patient safety of platelet aggregation inhibitors in the prevention of cardiovascular disease and ischemic stroke in older adults – a systematic review

  2017cites this paper
• The neuron‐astrocyte‐microglia triad in CA3 after chronic cerebral hypoperfusion in the rat: Protective effect of dipyridamole

  2017cites this paper
• Stroke.

  2017cites this paper
• One-year outcomes and secondary prevention in patients after acute minor stroke: results from the China National Stroke Registry

  2017cites this paper
• Antiplatelet Treatment in Stroke: New Insights.

  2016cites this paper
• Heterogeneous Causes of Stroke: Antithrombotics

  2016cites this paper
• Safety and efficacy of intensive vs. guideline antiplatelet therapy in high‐risk patients with recent ischemic stroke or transient ischemic attack: rationale and design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial (ISRCTN47823388)

  2015cites this paper
• Uptake of systematic reviews and meta-analyses based on individual participant data in clinical practice guidelines: descriptive study

  2015cites this paper
• Baseline characteristics, analysis plan and report on feasibility for the Prevention Of Decline in Cognition After Stroke Trial (PODCAST)

  2015cites this paper
• Personalized medicine and stroke prevention: where are we?

  2015cites this paper
• NATIONAL EVIDENCE-BASED GUIDELINE ON SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE IN TYPE 2 DIABETES Blood pressure lowering , lipid modification and anti-thrombotic therapy

  2015cites this paper
• Uso de dipiridamol como monoterapia para la prevención secundaria cardiovascular

  2015cites this paper
• Post‐stroke cognitive decline: an update and perspectives for clinical research

  2015cites this paper
• Stroke in patients with occlusion of the internal carotid artery: options for treatment

  2014cites this paper
• Antiplatelets in stroke prevention.

  2014cites this paper
• The Effect of a Slower than Standard Dose Escalation Scheme for Dipyridamole on Headaches in Secondary Prevention Therapy of Strokes: A Randomized, Open-Label Trial (DOSE)

  2014cites this paper
• Intracerebral hemorrhage in patients treated with intravenous thrombolysis for acute ischemic stroke

  2014cites this paper
• An assessment of the cost-effectiveness of magnetic resonance, including diffusion-weighted imaging, in patients with transient ischaemic attack and minor stroke: a systematic review, meta-analysis and economic evaluation.

  2014cites this paper
• Classical and pleiotropic actions of dipyridamole: Not enough light to illuminate the dark tunnel?

  2014cites this paper
• The neuron-astrocyte-microglia triad in a rat model of chronic cerebral hypoperfusion: protective effect of dipyridamole

  2014cites this paper
• TRIAL / STUDY PERSONNEL AND CONTACT DETAILS

  2014cites this paper
• Enfermedad cerebrovascular: incidencia y tratamiento actual

  2014cites this paper
• Secondary stroke prevention.

  2014cites this paper
• Management of ischaemic stroke in the acute setting: review of the current status

  2013cites this paper
• Sekundärprophylaxe des Schlaganfalls aus neurologischer Perspektive

  2013cites this paper
• The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials.

  2013influential citation
• Role of Antiplatelet Therapies in Preventing Atherothrombosis

  2013cites this paper
• Spray Drying as a Fast and Simple Technique for the Preparation of Extended Release Dipyridamole (DYP) Microparticles in a Fixed Dose Combination (FDC) Product with Aspirin

  2013cites this paper
• [Secondary prophylaxis of stroke from a neurological perspective].

  2013cites this paper
• Acute ischemic cerebrovascular events on antiplatelet therapy: what is the optimal prevention strategy?

  2013cites this paper
• Carotid Disease and Stroke

  2012cites this paper
• Secondary stroke prevention: misguided by guidelines?

  2012cites this paper
• Assessment of publication bias, selection bias, and unavailable data in meta-analyses using individual participant data: a database survey

  2012cites this paper
• Multiple versus one or more antiplatelet agents for preventing early recurrence after ischaemic stroke or transient ischaemic attack

  2012cites this paper
• Recommendations for Management of Patients with Carotid Stenosis

  2012cites this paper
• Improving stroke care: Quality of care and health education in patients with a stroke or transient ischemic attack

  2011cites this paper
• Update on selecting and adjusting antiplatelet therapy for prevention of noncardiogenic, recurrent ischemic stroke

  2011cites this paper
• Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke.

  2011cites this paper
• Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.

  2011cites this paper
• Dipyridamol effectief na TIA of herseninfarct

  2011cites this paper
• Antiplatelet therapy in secondary stroke prevention – state of the art

  2010cites this paper
• Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?

  2010cites this paper
• Missed opportunities to prevent stroke recurrence

  2010cites this paper
• Diabetes and the brain

  2010cites this paper
• Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events.

  2010cites this paper
• Ischaemic stroke – prevention is better than cure

  2010cites this paper
• Antithrombotische und Antikoagulanzientherapie nach Schlaganfall und transitorisch ischämischer Attacke

  2010cites this paper
• Recommendations for the management of patients with carotid stenosis.

  2010cites this paper
• [Antithrombotic and anticoagulation therapy after stroke and transient ischemic attacks].

  2010cites this paper
• Schlaganfallsekundärprävention bei Diabetespatienten

  2009cites this paper
• Patients Enrolled in Large Randomized Clinical Trials of Antiplatelet Treatment for Prevention After Transient Ischemic Attack or Ischemic Stroke Are Not Representative of Patients in Clinical Practice: The Netherlands Stroke Survey

  2009cites this paper
• Secondary prevention of stroke.

  2009cites this paper
• Representative of Patients in Clinical Practice : The Netherlands Stroke Survey for Prevention After Transient Ischemic Attack or Ischemic Stroke Are Not Patients Enrolled in Large Randomized Clinical Trials of Antiplatelet Treatment

  2009cites this paper
• Recent Publications on Medications and Pharmacy

  2009cites this paper
• Antithrombotic medication for stroke prevention

  2009cites this paper
• Thrombozytenfunktionshemmer in der akuten und langfristigen Schlaganfallprävention

  2009cites this paper
• Stroke and Diabetes Mellitus

  2009cites this paper
• Carotid Stenosis, Endarterectomy, and the Brain : Brain microcirculation, diffusion, and cognitive function before and after carotid endarterectomy in patients with a high-grade carotid stenosis

  2009cites this paper
• Medical prevention of stroke and stroke recurrence in patients with TIA and minor stroke

  2009cites this paper
• Recent Publications on Medications and Pharmacy

  2009cites this paper
• Antiplatelet agents in stroke prevention

  2009cites this paper
• ESPRIT: is aspirin plus dipyridamole superior to aspirin alone in TIA or minor stroke patients?

  2008cites this paper
• Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy

  2007cites this paper
• From the Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

  2007cites this paper
• Ischemic Stroke

  2005cites this paper